CYP1A1 and chronic myelogenous leukemia, BCR-ABL1 positive: In view of suchconflicting results, we have conducted a case-controlstudy in the Indian population to examine the associationof CYP1A1*2C polymorphism with CML riskand whether this polymorphism affects the therapeuticresponse of the patients to Imatinib.